A recent study reveals that patients who stop using popular GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds at a significantly accelerated pace than those who end conventional lifestyle regimens.
Published data in a prominent health publication shows that while overweight individuals often shed substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Users using these treatments should be aware of the danger of rapid rebound weight gain when the treatment concludes," warns expert Dr. Susan Jebb.
Such speed of recovery suggests a return to original weight within about a year and a half.
Comparing Treatments
The study, which reviewed dozens of trials involving over 9,000 of participants, compared the results of the injectable medications with other pills.
Scientists emphasize that people who shed pounds through diet and exercise typically see a more gradual creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Rapid Regain
Nutrition scientists propose the mode of action of the drugs explains the heightened regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 levels far above than normal may cause the system to produce less of its endogenous hormone, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement leads to appetite is uncontrolled, making excessive eating a significant risk."
A Chronic Condition?
Medical guidelines recommend the injections for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Professionals say that, due to the likelihood of weight regain, the therapy is often life-long.
This perspective is supported by drug manufacturers, who state that the findings "underscore the chronic nature of obesity," similar to managing conditions like diabetes.
User Accounts
Individuals who have stopped the medication report a powerful return of appetite.
"I experienced something activating and you become ravenous," described one woman.
This challenge is worsened if users have not developed sustainable dietary or behavioural changes during therapy.
Widespread Adoption
Figures indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is higher among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Finally, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a magic solution and maintained weight loss relies on ongoing lifestyle changes.
